DISEASE CHARACTERISTICS:

• Histologically confirmed angiosarcoma

  • Any stage disease
  • Must be deemed not surgically resectable (complete resection) and/or no other therapeutic modality is known to be curative
  • No angiosarcoma of a vessel wall
• Newly diagnosed or recurrent/refractory disease
• No prior tumor-related hemorrhage (any grade)
• Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan
• No CNS disease, brain metastases, or primary brain tumors

PATIENT CHARACTERISTICS:

• ECOG performance status of 0 or 1
• Absolute granulocyte count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Hemoglobin ≥ 9 gm/dL (transfusion and epoetin alfa allowed)
• Creatinine ≤ 1.5 times upper limit of normal (ULN)
• Urine protein:creatinine ratio ≤ 1.0
• Total bilirubin ≤ 1.5 mg/dL
• Aspartate aminotransferase < 5 times ULN
• Alkaline phosphatase < 5 times ULN
• PT/INR ≤ 1.5 times ULN
• PTT ≤ 1.5 times ULN
• Fertile patients must use effective contraception
• Ejection fraction > 49% for patients with prior anthracycline therapy, ischemic cardiac disease, or history of heart failure
• No uncontrolled active infection
• No uncontrolled high blood pressure (defined as > 150/100 mm Hg)
• No symptomatic congestive heart failure (New York Heart Association class II-IV), unstable angina, cardiac arrhythmia, or myocardial infarction within the past 6 months
• No psychiatric illness or social situation that would limit study compliance
• No serious, nonhealing wound, ulcer, or bone fracture
• No evidence of bleeding diathesis or coagulopathy
• No clinically significant peripheral vascular disease
• Not pregnant or nursing
• No seizures not controlled with standard medical therapy
• No embolic or hemorrhagic stroke or prior transient ischemic attack
• No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
• No significant traumatic injury within the past 6 weeks

PRIOR CONCURRENT THERAPY:

• No prior therapy with bevacizumab or other antiangiogenesis treatment
• No major surgical procedure or open biopsy within the past 6 weeks
• No more than 2 prior chemotherapy regimens
• No fine-needle aspiration or core-needle biopsy or other minor surgical procedure within the past 7 days
• No radiotherapy within the past 28 days
• No concurrent chronic daily treatment with aspirin > 325 mg/day or nonsteroidal anti-inflammatory medications
• No concurrent warfarin or any other anticoagulant (any dose)
• No concurrent radiotherapy
• No concurrent major surgery